Objective Tuberculosis kills three million each year and is a major public health problem in developing countries. Vaccination is a very cost efficient control strategy but campaigns with the presently available vaccine, Bacillus Calmette Guerin (BCG), has so far demonstrated very limited succes in the TB endemic countries. The objective of this grant application is the development of an improved vaccine against tuberculosis. If succesfull, the studies described will lead to the construction of an experimental vaccine, ready for clinical testing at the end of the project period. Only live vaccines efficiently induce protective immunity, and the present project is therefore focused on antigens secreted from the live metabolizing mycobacteria during growth as a source of protective antigens. Large scale production of Secreted proteins, state of the art procedures for their fractionation, and animal models for testing experimental vaccines have been established in the preceeding period. The proposed work continues along these lines and will contribute with new information on the parameters of importance for the protective efficacy of experimental vaccines. The work to be conducted will focus on the following topics: i) Construction of an experimental vaccine with high efficacy in animal models. ii) Extensive screening of human T cell responses to secreted protein fractions. iii) Detailed investigation of vaccine candidate antigens. At the end of the proposed project period identified key epitopes will be incorporated into either a subunit vaccins or expressed in hiqh quantities in a recombinant BCG carrier. Fields of science medical and health scienceshealth sciencespublic healthnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicinepneumologytuberculosismedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) FP3-STD 3 - Specific research and technological development programme (EEC) in the field of the life sciences and technologies for developing countries, 1990-1994 Topic(s) Data not available Call for proposal Data not available Funding Scheme CSC - Cost-sharing contracts Coordinator Statens Serum Institut EU contribution No data Address 5,Artillerivej 2300 Kobenhavn A Denmark See on map Total cost No data Participants (4) Sort alphabetically Sort by EU Contribution Expand all Collapse all ARMAUER HANSEN RESEARCH INSTITUTE Ethiopia EU contribution No data Address 1005 2003 ADDIS ABEBA See on map Total cost No data National Institute of Public Health Norway EU contribution No data Address 75,Geitmyrsveien 0462 Oslo See on map Total cost No data Universidade do Porto Portugal EU contribution No data Address 823,Rua do Campo Allegre 4100 Porto See on map Total cost No data University of Oslo Norway EU contribution No data Address 0027 Oslo See on map Total cost No data
